Skip to content
The People's CodeSearch
Menu

Changes to the Code

S. 3551 · PROTECT for Rare Act ·

In committee · step 2 of 5

Sections are cited like “7 U.S.C. § 2012”: 7 of the , 2012.

26 U.S.C. § 9826 Expedited process for review associated with certain drugs used in treatment or management of a rare disease or condition New section

+12 −0Shown
More for 26 U.S.C. § 9826
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Subchapter B of chapter 100 of the Internal Revenue Code of 1986 is amended by adding at the end the following new section:9826. Expedited process for review associated with certain drugs used in treatment or management of a rare disease or condition A group health plan shall provide an expedited process pursuant to section 2719 of the Public Health Service Act (42 U.S.C. 300gg–19) by which a participant or beneficiary, or a designee or prescribing physician (or other prescriber, as appropriate) of the participant or beneficiary, may appeal any denial of coverage for a drug or biological product— (1) approved under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) or licensed under section 351 of the Public Health Service Act (42 U.S.C. 262); (2) for which the use is related to treatment or management of a disease or condition affecting 200,000 or fewer individuals in the United States; and (3) the use of which is supported by— (A) the labeling for the drug or biological product approved pursuant to such section 505 or 351; or (B) peer-reviewed literature, including clinical guidelines, and that is not reviewed unfavorably in the compendia described in section 1927(g)(1)(B)(i) of the Social Security Act (42 U.S.C. 1396r–8(g)(1)(B)(i)) and is not listed as a contraindication in such approved labeling..

    The section already has a provision under this letter or number, so it would have two.

The Code already has a 26 U.S.C. § 9826, a different section added since this bill was written, so this would be a second section under that number.

§ 9826(1)–(3)

WhereMarkThe Code nowMarkAs the bill would leave it
§ 9826. [inserted: Expedited process for review associated with certain drugs used in treatment or management of a rare disease or condition]
[inserted: A group health plan shall provide an expedited process pursuant to section 2719 of the Public Health Service Act (42 U.S.C. 300gg–19) by which a participant or beneficiary, or a designee or prescribing physician (or other prescriber, as appropriate) of the participant or beneficiary, may appeal any denial of coverage for a drug or biological product—]
(1)(1) [inserted: ]
[inserted: approved under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) or licensed under section 351 of the Public Health Service Act (42 U.S.C. 262);]
(2)(2) [inserted: ]
[inserted: for which the use is related to treatment or management of a disease or condition affecting 200,000 or fewer individuals in the United States; and]
(3)(3) [inserted: ]
[inserted: the use of which is supported by—]
(3)(A)(A) [inserted: ]
[inserted: the labeling for the drug or biological product approved pursuant to such section 505 or 351; or]
(3)(B)(B) [inserted: ]
[inserted: peer-reviewed literature, including clinical guidelines, and that is not reviewed unfavorably in the compendia described in section 1927(g)(1)(B)(i) of the Social Security Act (42 U.S.C. 1396r–8(g)(1)(B)(i)) and is not listed as a contraindication in such approved labeling.]

42 U.S.C. § 1395x Definitions

+5 −3Shown
More for 42 U.S.C. § 1395x
Read § 1395xOnly this section
4 changes the bill asks for here, 4 carried out
  1. Carried out:

    in subparagraph (A), by inserting after regimen the following: , or used in the treatment or management of a disease or condition affecting 200,000 or fewer individuals in the United States,; and

  2. Carried out:

    in subclause (I), by striking , or at the end and inserting a semicolon;

  3. Carried out:

    in subclause (II), by striking the period at the end and inserting ; or; and

  4. Carried out:

    by adding at the end the following new subclause:(III) in the case of a drug that is used in the treatment or management of a disease or condition affecting 200,000 or fewer individuals in the United States, such use is supported by peer-reviewed medical literature, including clinical guidelines, and is not specifically listed …

§ 1395x(t)–(u)

Start of § 1395x to (t) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(t)(1)(1) (1)
The term “drugs” and the term “biologicals”, except for purposes of subsection (m)(5) of this section and paragraph (2), include only such drugs (including contrast agents) and biologicals, respectively, as are included (or approved for inclusion) in the United States Pharmacopoeia, the National Formulary, or the United States Homeopathic Pharmacopoeia, or in New Drugs or Accepted Dental Remedies (except for any drugs and biologicals unfavorably evaluated therein), or as are approved by the pharmacy and drug therapeutics committee (or equivalent committee) of the medical staff of the hospital furnishing such drugs and biologicals for use in such hospital.The term “drugs” and the term “biologicals”, except for purposes of subsection (m)(5) of this section and paragraph (2), include only such drugs (including contrast agents) and biologicals, respectively, as are included (or approved for inclusion) in the United States Pharmacopoeia, the National Formulary, or the United States Homeopathic Pharmacopoeia, or in New Drugs or Accepted Dental Remedies (except for any drugs and biologicals unfavorably evaluated therein), or as are approved by the pharmacy and drug therapeutics committee (or equivalent committee) of the medical staff of the hospital furnishing such drugs and biologicals for use in such hospital.
(t)(2)(2) (2)
(t)(2)(A)(A) (A)
For purposes of paragraph (1), the term “drugs” also includes any drugs or biologicals used in an anticancer chemotherapeutic regimen for a medically accepted indication (as described in subparagraph (B)).For purposes of paragraph (1), the term “drugs” also includes any drugs or biologicals used in an anticancer chemotherapeutic regimen[inserted: ,] [inserted: or used in the treatment or management of a disease or condition affecting 200,000 or fewer individuals in the United States, ]for a medically accepted indication (as described in subparagraph (B)).
(t)(2)(B)(B) (B)
In subparagraph (A), the term “medically accepted indication”, with respect to the use of a drug, includes any use which has been approved by the Food and Drug Administration for the drug, and includes another use of the drug if—In subparagraph (A), the term “medically accepted indication”, with respect to the use of a drug, includes any use which has been approved by the Food and Drug Administration for the drug, and includes another use of the drug if—
(t)(2)(B)(i)(i) (i)
the drug has been approved by the Food and Drug Administration; andthe drug has been approved by the Food and Drug Administration; and
(t)(2)(B)(ii)(ii) (ii)
(t)(2)(B)(ii)(I)(I) (I)
such use is supported by one or more citations which are included (or approved for inclusion) in one or more of the following compendia: the American Hospital Formulary Service-Drug Information, the American Medical Association Drug Evaluations, the United States Pharmacopoeia-Drug Information (or its successor publications), and other authoritative compendia as identified by the Secretary, unless the Secretary has determined that the use is not medically appropriate or the use is identified as not indicated in one or more such compendia[struck: , or]such use is supported by one or more citations which are included (or approved for inclusion) in one or more of the following compendia: the American Hospital Formulary Service-Drug Information, the American Medical Association Drug Evaluations, the United States Pharmacopoeia-Drug Information (or its successor publications), and other authoritative compendia as identified by the Secretary, unless the Secretary has determined that the use is not medically appropriate or the use is identified as not indicated in one or more such compendia[inserted: ;]
(t)(2)(B)(ii)(II)(II) (II)
the carrier involved determines, based upon guidance provided by the Secretary to carriers for determining accepted uses of drugs, that such use is medically accepted based on supportive clinical evidence in peer reviewed medical literature appearing in publications which have been identified for purposes of this subclause by the Secretary[struck: .]the carrier involved determines, based upon guidance provided by the Secretary to carriers for determining accepted uses of drugs, that such use is medically accepted based on supportive clinical evidence in peer reviewed medical literature appearing in publications which have been identified for purposes of this subclause by the Secretary[inserted: ; or]
(t)(2)(B)(ii)(III)(III) [inserted: ]
[inserted: in the case of a drug that is used in the treatment or management of a disease or condition affecting 200,000 or fewer individuals in the United States, such use is supported by peer-reviewed medical literature, including clinical guidelines, and is not specifically listed as not indicated in one or more of the compendia described in section 1927(g)(1)(B)(i), or listed as contraindicated in the labeling approved by the Food and Drug Administration.]
(t)(2)(B)The Secretary may revise the list of compendia in clause (ii)(I) as is appropriate for identifying medically accepted indications for drugs. On and after January 1, 2010, no compendia may be included on the list of compendia under this subparagraph unless the compendia has4 a publicly transparent process for evaluating therapies and for identifying potential conflicts of interests.The Secretary may revise the list of compendia in clause (ii)(I) as is appropriate for identifying medically accepted indications for drugs. On and after January 1, 2010, no compendia may be included on the list of compendia under this subparagraph unless the compendia has4 a publicly transparent process for evaluating therapies and for identifying potential conflicts of interests.
(u)(u) Provider of services(u) Provider of services
The term “provider of services” means a hospital, critical access hospital, rural emergency hospital, skilled nursing facility, comprehensive outpatient rehabilitation facility, home health agency, hospice program, or, for purposes of section 1395f(g) and section 1395n(e) of this title, a fund.The term “provider of services” means a hospital, critical access hospital, rural emergency hospital, skilled nursing facility, comprehensive outpatient rehabilitation facility, home health agency, hospice program, or, for purposes of section 1395f(g) and section 1395n(e) of this title, a fund.

Rest of § 1395x unchanged

42 U.S.C. § 1396r–8 Payment for covered outpatient drugs

+13 −3Shown
More for 42 U.S.C. § 1396r–8
Read § 1396r–8Only this section
2 changes the bill asks for here, 2 carried out
  1. Carried out:

    Section 1927(k)(6) of the Social Security Act (42 U.S.C. 1396r–8(k)(6)) is amended to read as follows:(6) Medically accepted indication.— The term “medically accepted indication” means any use for a covered outpatient drug— (A) which is approved under the Federal Food, Drug, and Cosmetic Act; (B) which is supported by one or more citations included or approved for inclusion in …

  2. Carried out:

    Section 1927(d)(4)(C) of the Social Security Act (42 U.S.C. 1396r–8(d)(4)(C)) is amended by striking compendia and inserting sources.

§ 1396r–8(d)(4)Requirements for formularies(B)–(E)

Start of § 1396r–8 to (d)(4)(A) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(B)(B) (B)
Except as provided in subparagraph (C), the formulary includes the covered outpatient drugs of any manufacturer which has entered into and complies with an agreement under subsection (a) (other than any drug excluded from coverage or otherwise restricted under paragraph (2)).Except as provided in subparagraph (C), the formulary includes the covered outpatient drugs of any manufacturer which has entered into and complies with an agreement under subsection (a) (other than any drug excluded from coverage or otherwise restricted under paragraph (2)).
(C)(C) (C)
A covered outpatient drug may be excluded with respect to the treatment of a specific disease or condition for an identified population (if any) only if, based on the drug’s labeling (or, in the case of a drug the prescribed use of which is not approved under the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 301 et seq.] but is a medically accepted indication, based on information from the appropriate [struck: compendia] described in subsection (k)(6)), the excluded drug does not have a significant, clinically meaningful therapeutic advantage in terms of safety, effectiveness, or clinical outcome of such treatment for such population over other drugs included in the formulary and there is a written explanation (available to the public) of the basis for the exclusion.A covered outpatient drug may be excluded with respect to the treatment of a specific disease or condition for an identified population (if any) only if, based on the drug’s labeling (or, in the case of a drug the prescribed use of which is not approved under the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 301 et seq.] but is a medically accepted indication, based on information from the appropriate [inserted: sources] described in subsection (k)(6)), the excluded drug does not have a significant, clinically meaningful therapeutic advantage in terms of safety, effectiveness, or clinical outcome of such treatment for such population over other drugs included in the formulary and there is a written explanation (available to the public) of the basis for the exclusion.
(D)(D) (D)
The State plan permits coverage of a drug excluded from the formulary (other than any drug excluded from coverage or otherwise restricted under paragraph (2)) pursuant to a prior authorization program that is consistent with paragraph (5).The State plan permits coverage of a drug excluded from the formulary (other than any drug excluded from coverage or otherwise restricted under paragraph (2)) pursuant to a prior authorization program that is consistent with paragraph (5).
(E)(E) (E)
The formulary meets such other requirements as the Secretary may impose in order to achieve program savings consistent with protecting the health of program beneficiaries.The formulary meets such other requirements as the Secretary may impose in order to achieve program savings consistent with protecting the health of program beneficiaries.

§ 1396r–8(k)Definitions(5)–(7)

(d)(4)–(k)(5) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(5)(B)(B) (B)
in the packaging, repackaging, labeling, relabeling, or distribution of prescription drug products.in the packaging, repackaging, labeling, relabeling, or distribution of prescription drug products.
(5)Such term does not include a wholesale distributor of drugs or a retail pharmacy licensed under State law.Such term does not include a wholesale distributor of drugs or a retail pharmacy licensed under State law.
(6)(6) Medically accepted indication(6) Medically accepted indication[inserted: .—]
[inserted: The term “medically accepted indication” means any use for a covered outpatient drug—]
(6)(A)(A) [inserted: ]
[inserted: which is approved under the Federal Food, Drug, and Cosmetic Act;]
(6)(B)(B) [inserted: ]
[inserted: which is supported by one or more citations included or approved for inclusion in any of the compendia described in subsection (g)(1)(B)(i); or]
(6)(C)(C) [inserted: ]
[inserted: which, in the case of a drug used to treat or manage a disease or condition affecting 200,000 or fewer individuals in the United States—]
(6)(C)(i)(i) [inserted: ]
[inserted: is a use of such drug that is supported by peer-reviewed medical literature, clinical guidelines, or an expert in such disease or condition, as identified by a medical society involved in the treatment or management of such disease or condition; and]
(6)(C)(ii)(ii) [inserted: ]
[inserted: is a use of such drug that is not listed as not indicated in the compendia described in subsection (g)(1)(B)(i), or listed as contraindicated in the labeling approved by the Food and Drug Administration.]
(6)[struck: The term “medically accepted indication” means any use for a covered outpatient drug which is approved under the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 301 et seq.] or the use of which is supported by one or more citations included or approved for inclusion in any of the compendia described in subsection (g)(1)(B)(i).]
(7)(7) Multiple source drug; innovator multiple source drug; noninnovator multiple source drug; single source drug(7) Multiple source drug; innovator multiple source drug; noninnovator multiple source drug; single source drug
(7)(A)(A) Defined(A) Defined
(7)(A)(i)(i) Multiple source drug(i) Multiple source drug
The term “multiple source drug” means, with respect to a rebate period, a covered outpatient drug, including a drug product approved for marketing as a non-prescription drug that is regarded as a covered outpatient drug under paragraph (4), for which there 2 at least 1 other drug product which—The term “multiple source drug” means, with respect to a rebate period, a covered outpatient drug, including a drug product approved for marketing as a non-prescription drug that is regarded as a covered outpatient drug under paragraph (4), for which there 2 at least 1 other drug product which—

Rest of § 1396r–8 unchanged

42 U.S.C. § 1395w–104 Beneficiary protections for qualified prescription drug coverage

Couldn't place the change
More for 42 U.S.C. § 1395w–104
Read § 1395w–104Only this section

The bill's words for this section

  1. Not carried out:

    Section 1860D–2(e)(4)(A)(i) of the Social Security Act (42 U.S.C. 1395w–104(e)(4)(A)(i)) is amended, in the matter preceding subclause (I), by inserting or in the case of a covered part D drug used in the treatment or management of a disease or condition affecting 200,000 or fewer individuals in the United States, after regimen,

    “regimen,” isn't in § 1395w–104(i) in the Code as we have it. The law may have changed since the bill was drafted.

    Technical detail“regimen,” not found in /us/usc/t42/s1395w–104/i

Step through the changes